Lonza and Eclipse Therapeutics Sign Development and Manufacturing Deal

Lonza says it has signed an agreement with private biotechnology company Eclipse Therapeutics (San Diego, CA) for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Lonza’s light path development services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Lonza will produce phase 1 clinical material at its development and manufacturing facility at Slough, U.K., under the deal. Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers